Continuing Pharmacy Education / CE Master List / Hormone Therapy’s Twin Faces: Sorting Science from Misconception-RECORDED WEBINAR
Please use this button to register in our system as a new user, or to purchase a CE Activity.
For free CE's, returning users can simply click the "TAKE TEST/EVALUATION" button on the right.
Please use this button when you have completed the CE Activity and are ready to take the quiz and complete the evaluation.

Hormone Therapy’s Twin Faces: Sorting Science from Misconception-RECORDED WEBINAR

About this Course

This course is a recorded (home study version) of the 2025 CE Finale Encore Webinars.

 

Learning Objectives

Upon completion of this application based CE Activity, a pharmacist will be able to:

  • Discuss the clinical evidence on safety, efficacy, and patient outcomes for hormone replacement therapy (HRT), highlighting areas of misconception or confusion
  • Compare HRT options and bioidenticals, including mechanisms of action, formulations, and regulatory pathways
  • Apply guidelines and evidence-based recommendations to individualize patient counseling and therapeutic decision-making when managing HRT

Release and Expiration Dates

Released:  December 19, 2025
Expires:  December 19, 2028

Course Fee

$17 Pharmacist

ACPE UAN

0009-0000-25-067-H01-P

Session Code

25RW67-TFM98

Accreditation Hours

1.0 hours of CE

Additional Information

 

How to Complete Evaluation:  When you are ready to submit quiz answers, go to the BLUE take test/evaluation button.

Accreditation Statement

The University of Connecticut School of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Pharmacists and Pharmacy Technicians are eligible to participate in this application-based activity and will receive up to 1.0 CE Hours (or 0.1 CEUs)  for completing the activity ACPE UAN 0009-0000-25-067-H01-P, passing the quiz with a grade of 70% or better, and completing an online evaluation. Statements of credit are available via the CPE Monitor online system and your participation will be recorded with CPE Monitor within 72 hours of submission.

Grant Funding

There is no grant funding for this activity.

Faculty

Kelsey Giara, PharmD
Freelance Medical Writer
Pelham, NH

Faculty Disclosure

In accordance with the Accreditation Council for Pharmacy Education (ACPE) Criteria for Quality and Interpretive Guidelines, The University of Connecticut School of Pharmacy requires that faculty disclose any relationship that the faculty may have with commercial entities whose products or services may be mentioned in the activity.

  • Kelsey Giara has no relationships with ineligible companies

Disclaimer

The material presented here does not necessarily reflect the views of The University of Connecticut School of Pharmacy or its co-sponsor affiliates. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.

Content

Posttest

1. Which statement BEST reflects current evidence regarding the safety of hormone replacement therapy (HRT)?
A. HRT is associated with increased cardiovascular and cancer risk regardless of age or timing
B. HRT’s benefit-risk profile is favorable when started before age 60 or within 10 years of menopause
C. HRT should generally be avoided due to persistent risks identified in early WHI trial reports

*

2. Which menopausal symptom is MOST effectively treated with systemic estrogen therapy?
A. Vasomotor symptoms, such as hot flashes and night sweats
B. Isolated vaginal dryness without other menopausal complaints
C. Mild urinary symptoms without associated vasomotor complaints

*

3. Which statement accurately compares FDA-approved bioidentical hormones with compounded bioidentical hormone products?
A. Both FDA-approved and compounded bioidentical hormones undergo the same regulatory review
B. Compounded bioidentical hormones are preferred because they are more natural and tailored to patient needs
C. Only FDA-approved bioidentical hormones have standardized dosing and known safety profiles

*

4. Which statement BEST describes the FDA’s November 2025 updates to boxed warning language for HRT?
A. All boxed warnings were removed after evidence showed WHI studies reflected inaccurate data regarding HRT risks
B. Boxed warnings were expanded to emphasize cardiovascular and dementia risks in newly menopausal women
C. Boxed warnings were revised to better reflect age- and timing-specific risk while retaining key safety information

*

5. A 52-year-old woman who is 2 years postmenopausal presents with bothersome hot flashes and night sweats that are disrupting sleep and daily functioning. She has an intact uterus, no history of cardiovascular disease or venous thromboembolism, and is concerned about cancer risk after reading older media reports about hormone therapy. Which counseling and treatment approach is MOST appropriate?
A. Recommend low-dose transdermal estrogen combined with a progestin and discuss individualized benefits and risks
B. Advise against hormone therapy due to patient age and persistent safety concerns and recommend nonhormonal options only
C. Suggest compounded bioidentical estrogen therapy to minimize systemic exposure and long-term cardiovascular and cancer risks

Handouts

Download

VIDEO